Evidence Level
NEM has a focused evidence base with consistently positive results. The pivotal Ruff et al. (2009) trial demonstrated significant pain and stiffness reduction within 10 days, much faster than the 4-8 weeks typical for glucosamine or chondroitin. A follow-up trial by Ruff et al. (2018) extended these findings to healthy active adults with exercise-related joint discomfort. The rapid onset is attributed to NEM delivering a pre-formed matrix of joint-supporting compounds (collagen, chondroitin, HA, growth factors) in their natural ratios, rather than isolated components. Brunello and Secker (2016) confirmed these findings in an independent trial. While the evidence is more limited in scope than glucosamine or chondroitin, the consistency of results and unique rapid-onset profile make NEM a notable option in joint health supplementation.